Methods and compositions for administration of iron for the treatment of restless leg syndrome
A method of treating Restless Leg Syndrome, includes administering to a subject an iron complex having an iron release rate greater than IDI. The iron release rate is determined at a concentration of at least 2,000 μg/dl.
1. A method of treating Restless Leg Syndrome, comprising administering to a subject an iron sucrose having an iron release rate greater than IDI, wherein the iron release rate is determined at a concentration of at least 2,000 μg/dl.
2. The method of claim 1 , wherein the administering is parenterally.
3. The method of claim 1 , wherein an amount of iron administered is 100 mg-2000 mg.
4. The method of claim 1 , further comprising a second administration of said iron complex upon recurrence of at least one symptom of Restless Leg Syndrome.
5. The method of claim 1 , further comprising a second administration of said iron complex after 4 days-12 months after the first administration.
6. The method of claim 1 , wherein the iron sucrose is iron sucrose injection USP.
7. A method of treating Restless Leg Syndrome, comprising administering to a subject an iron sucrose having an iron release rate of at least 115 μg/dl at a concentration of 3438 μg/dl by the alumina column test.
8. The method of claim 7 , wherein the release rate is at least 120 μg/dl.
9. The method of claim 7 , wherein the release rate is at least 140 μg/dl.
10. The method of claim 7 , wherein the administering is intravenous.
11. The method of claim 7 , wherein an amount of iron administered is 100 mg-2000 mg.
12. The method of claim 7 , further comprising a second administration of said iron complex upon recurrence of at least symptom of Restless Leg Syndrome.
13. The method of claim 7 , further comprising a second administration of said iron complex after 4 days-12 months after the first administration.
14. The method of claim 8 , wherein an amount of iron is 100 mg-2000 mg.
15. The method of claim 9 , wherein an amount of iron is 100 mg-2000 mg.
16. A kit, comprising:
an iron sucrose composition having a release rate greater than IDI,
a syringe, and
a needle for the syringe, wherein the iron release rare is determined at a concentration of at least 2,000 μg/dl.